| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-07-30 | Biophytis (France) | nomination |
Nomination | |||
| 2015-07-30 | Argen-X (Belgium - The Netherlands) University of Bern (Switzerland) | ARGX-110-based therapies | hematological cancers | licensing |
Cancer - Oncology | Licensing agreement |
| 2015-07-29 | Boehringer Ingelheim (Germany) Hanmi Pharmaceutical (South Korea) | Olmutinib (BI 1482694; HM61713) | lung cancer | licensing development commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-07-29 | Novartis (Switzerland) Mereo BioPharma (UK) | compounds including BPS-804, BCT-197 and BGS-649 | improvement of bone density in brittle bone syndrome, acute exacerbations in COPD, normalization of testosterone levels in obese men with hypogonadotrophic hypogonadism | collaboration |
Bone diseases - Endocrinological diseases - Hormonal diseases - Inflammatory diseases - Pulmonary diseases - Rare diseases - Respiratory diseases | Collaboration agreement |
| 2015-07-29 | Txcell (France) Masthercell (Belgium) | Ovasave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy) | Crohn disease | manufacturing production |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Production agreement |
| 2015-07-29 | BMS (USA - NY) Kyowa Hakko Kirin (Japan) | mogamulizumab and Opdivo® (nivolumab) | advanced or metastatic solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-07-29 | Complix (Belgium) | nomination |
Autoimmune diseases - Cancer - Oncology | Nomination | ||
| 2015-07-28 | Apogenix (Germany) R-Biopharm (Germany) | companion diagnostic tests for APG101 | development |
Cancer - Oncology | Development agreement | |
| 2015-07-27 | Keryx Biopharmaceuticals (USA - NY) | nomination |
Nomination | |||
| 2015-07-27 | Aegerion Pharmaceuticals (USA - MA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-07-27 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-07-27 | AstraZeneca (UK) Sanofi (France) | Caprelsa® (vandetanib) | symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease | product acquisition |
Cancer - Oncology - Rare diseases | Product acquisition |
| 2015-07-27 | Drugs for Neglected Diseases initiative (DNDi) (Switzerland) Takeda Pharmaceutical (Japan) | aminopyrazole series | visceral leishmaniasis | collaboration |
Infectious diseases - Parasitic diseases | Collaboration agreement |
| 2015-07-24 | Molecular Partners (Switzerland) Roche (Switzerland) | DARPin® biologics conjugated to toxic agents | cancer | R&D |
Cancer - Oncology | Termination of an agreement |
| 2015-07-24 | Evotec (Germany) Gladstone Institutes (USA) | Alzheimer’s disease | R&D |
Neurodegenerative diseases | R&D agreement | |
| 2015-07-24 | AstraZeneca (UK) Fujifilm Kyowa Kirin Biologics (Japan) | FKB238 | solid tumors | joint-venture |
Cancer - Oncology | Joint-venture agreement |
| 2015-07-23 | Morphosys (Germany) Novartis (Switzerland) | therapeutic antibodies | R&D |
Inflammatory diseases | Milestone | |
| 2015-07-23 | Merck Serono (Germany) BioMed X (Germany) | collaboration R&D |
Cancer - Oncology | Collaboration agreement | ||
| 2015-07-23 | Paion (Germany) Ono Pharmaceutical (Japan) | remimazolam | general anaesthesia | termination of a licensing agreement |
CNS diseases | Termination of an agreement |
| 2015-07-23 | Valneva (France- Austria) PaxVax (USA - CA) | Dukoral®, Vivotif® | cholera, typhoid | marketing distribution |
Infectious diseases | Distribution agreement |
